KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges: 2009-2025

Historic Amortization of Deferred Charges for Pacira BioSciences (PCRX) over the last 3 years, with Sep 2025 value amounting to $626,000.

  • Pacira BioSciences' Amortization of Deferred Charges fell 25.48% to $626,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 6.64%. This contributed to the annual value of $3.1 million for FY2024, which is 4.47% up from last year.
  • Per Pacira BioSciences' latest filing, its Amortization of Deferred Charges stood at $626,000 for Q3 2025, which was down 26.27% from $849,000 recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Amortization of Deferred Charges ranged from a high of $937,000 in Q1 2023 and a low of $626,000 during Q3 2025.
  • Its 3-year average for Amortization of Deferred Charges is $767,818, with a median of $763,000 in 2024.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first declined by 27.32% in 2024, then grew by 24.08% in 2025.
  • Pacira BioSciences' Amortization of Deferred Charges (Quarterly) stood at $685,000 in 2023, then grew by 23.50% to $846,000 in 2024, then decreased by 25.48% to $626,000 in 2025.
  • Its last three reported values are $626,000 in Q3 2025, $849,000 for Q2 2025, and $845,000 during Q1 2025.